Department of Health and Human Services December 13, 2021 – Federal Register Recent Federal Regulation Documents

Single-Source Supplement for Title X Services in Texas
Document Number: 2021-26850
Type: Notice
Date: 2021-12-13
Agency: Department of Health and Human Services
The Office of Population Affairs (OPA) announces the award of a single-source supplement to provide Title X family planning services in Texas to Women's Health and Family Planning Association of Texas (d.b.a. Every Body Texas). The supplement will enable Every Body Texas to expand provision of emergency contraception and other family planning services to clients across the state of Texas to address the anticipated increased demand for family planning services following passage of TX SB8.
Proposed Information Collection Activity; Electronic Document Exchange (OMB No.: 0970-0435)
Document Number: 2021-26847
Type: Notice
Date: 2021-12-13
Agency: Department of Health and Human Services, Administration for Children and Families
The Office of Child Support Enforcement (OCSE), Administration for Children and Families (ACF), is requesting the federal Office of Management and Budget (OMB) to approve the Electronic Document Exchange (EDE), with minor revisions, for an additional three years. State child support agencies use the EDE to improve case processing. The current OMB approval expires on June 30, 2022.
Cover Letter Attachments for Controlled Correspondences and Abbreviated New Drug Application Submissions; Draft Guidance for Industry; Availability
Document Number: 2021-26893
Type: Notice
Date: 2021-12-13
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled ``Cover Letter Attachments for Controlled Correspondences and Abbreviated New Drug Application Submissions.'' This guidance is intended to assist prospective applicants, applicants, and holders of abbreviated new drug applications (ANDAs) with optional attachments that can be used when preparing cover letters that accompany controlled correspondence to the Office of Generic Drugs (OGD), as well as original ANDAs, amendments to ANDAs, and supplements to approved ANDAs submitted to FDA.
Actavis LLC, et al.; Withdrawal of Approval of Six Abbreviated New Drug Applications
Document Number: 2021-26892
Type: Notice
Date: 2021-12-13
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA or Agency) is withdrawing approval of six abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
Oncologic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments
Document Number: 2021-26891
Type: Notice
Date: 2021-12-13
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Oncologic Drugs Advisory Committee. The general function of the committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.
Q3C(R8) Impurities: Guidance for Residual Solvents; International Council for Harmonisation; Guidance for Industry; Availability
Document Number: 2021-26889
Type: Notice
Date: 2021-12-13
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled ``Q3C(R8) Impurities: Guidance for Residual Solvents.'' The guidance was prepared under the auspices of the International Council for Harmonisation (ICH), formerly the International Conference on Harmonisation. This guidance provides recommendations for permitted daily exposures (PDEs) for three additional residual solvents: 2-Methyltetrahydrofuran, cyclopentyl methyl ether, and tert-butyl alcohol. The PDEs were developed according to the methods for establishing exposure limits included in the guidance for industry ``Q3C: Impurities Residual Solvents'' (Q3C guidance). The Q3C PDE levels are added and revised as new toxicological data for solvents become available. This guidance finalizes the draft guidance entitled ``Q3C(R8) Recommendations for the Permitted Daily Exposures for Three Solvents2-Methyltetrahydrofuran, Cyclopentyl Methyl Ether, and Tert-Butyl AlcoholAccording to the Maintenance Procedures for the Guidance Q3C Impurities: Residual Solvents'' issued on May 27, 2020.
National Institute of Neurological Disorders and Stroke Notice of Closed Meeting
Document Number: 2021-26866
Type: Notice
Date: 2021-12-13
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of Biomedical Imaging and Bioengineering; Notice of Meeting
Document Number: 2021-26930
Type: Notice
Date: 2021-12-13
Agency: Department of Health and Human Services, National Institutes of Health
Medical Devices; Neurological Devices; Classification of the Temporary Coil Embolization Assist Device
Document Number: 2021-26926
Type: Rule
Date: 2021-12-13
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA or we) is classifying the temporary coil embolization assist device into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for the temporary coil embolization assist device's classification. We are taking this action because we have determined that classifying the device into class II (special controls) will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices.
Request for Public Comment: 60-Day Proposed Information Collection: Addendum to Declaration for Federal Employment, Child Care and Indian Child Care Worker Positions (OMB No. 0917-0028)
Document Number: 2021-26925
Type: Notice
Date: 2021-12-13
Agency: Department of Health and Human Services, Indian Health Service
In compliance with the Paperwork Reduction Act of 1995, the Indian Health Service (IHS) invites the general public to take this opportunity to comment on the information collection titled, ``Addendum to Declaration for Federal Employment, Child Care and Indian Child Care Worker Positions,'' Office of Management and Budget (OMB) Control Number 0917-0028. A copy of the supporting statement is available at www.regulations.gov (see Docket ID: IHS_FRDOC_0001).
Medical Devices; Gastroenterology-Urology Devices; Classification of the Pressure Ulcer Management Tool
Document Number: 2021-26924
Type: Rule
Date: 2021-12-13
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA or we) is classifying the pressure ulcer management tool into class I. We are taking this action because we have determined that classifying the device into class I will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices.
Bowel Cleansing for Colonoscopy: Efficacy and Safety Considerations for Developing New Products; Draft Guidance for Industry; Availability
Document Number: 2021-26923
Type: Notice
Date: 2021-12-13
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled ``Bowel Cleansing for Colonoscopy: Efficacy and Safety Considerations for Developing New Products.'' The purpose of this draft guidance is to provide FDA's current thinking regarding the necessary attributes of patients for enrollment in clinical trials, efficacy assessments, and safety assessments. The draft guidance is intended to serve as a focus for continued discussion among FDA's Division of Gastroenterology, pharmaceutical sponsors, the academic community, and the public.
Agency Forms Undergoing Paperwork Reduction Act Review
Document Number: 2021-26903
Type: Notice
Date: 2021-12-13
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
Agency Forms Undergoing Paperwork Reduction Act Review
Document Number: 2021-26902
Type: Notice
Date: 2021-12-13
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
National Eye Institute; Notice of Closed Meeting
Document Number: 2021-26922
Type: Notice
Date: 2021-12-13
Agency: Department of Health and Human Services, National Institutes of Health
Proposed Information Collection Activity; Federal Tax Refund Offset, Administrative Offset, and Passport Denial
Document Number: 2021-26916
Type: Notice
Date: 2021-12-13
Agency: Department of Health and Human Services, Administration for Children and Families
The Office of Child Support Enforcement (OCSE), Administration for Children and Families (ACF) is requesting the federal Office of Management and Budget (OMB) to approve the Federal Tax Refund Offset, Administrative Offset, and Passport Denial with minor edits to the ``Comments'' section of the record specifications to clarify the corresponding fields for an additional three years. The current OMB approval expires on June 30, 2022.
Proposed Information Collection Activity; Regional Partnership Grants National Cross-Site Evaluation and Evaluation Technical Assistance (OMB #0970-0527)
Document Number: 2021-26913
Type: Notice
Date: 2021-12-13
Agency: Department of Health and Human Services, Administration for Children and Families
The Children's Bureau (CB), Administration for Children and Families (ACF), U.S. Department of Health and Human Services (HHS), is requesting an extension with minor changes to the approved information collection: Regional Partnership Grants National Cross-Site Evaluation and Evaluation Technical Assistance (OMB #0970-0527). The proposed information collection will be used in a national cross-site evaluation of the fifth and sixth cohorts of CB's Regional Partnership Grants (RPG). The cross-site evaluation will use surveys, interviews, progress reports, and data on participant enrollment, services, and outcomes.
Proposed Information Collection Activity; Administration for Native Americans Annual Data Report (ADR) (OMB #0970-0475)
Document Number: 2021-26912
Type: Notice
Date: 2021-12-13
Agency: Department of Health and Human Services, Administration for Children and Families
The Administration for Children and Families' (ACF) Administration for Native Americans (ANA) is requesting a 2-year extension to the following information collection: Annual Data Report (ADR) (OMB #0970-0475; expiration date: 2/28/2022). There are no changes requested to the form.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.